Evotec SE (EVT.DE) XETRA
5.10
-0.21(-3.96%)
Currency In EUR
- General
- Statistics
- Historical Data
- Profile
- Financials
Evotec SE
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
4766
First IPO Date
November 12, 1999
Key Executives
| Name | Title | Pay | Year Born |
| Christian Wojczewski | CEO & Chairperson of the Management Board | 2.5M | 1973 |
| Ian Hunneyball | Senior Vice President of Programme Management & Clinical Operations | 116,000 | 1950 |
| Ingrid Mller | Chief Operating Officer & Member of Management Board | 616,000 | 1972 |
| Cord Dohrmann | Chief Scientific Officer & Member of Management Board | 763,000 | 1964 |
| Aurelie Dalbiez | Chief People Officer & Member of Management Board | 958,000 | 1977 |
| Paul Hitchin | Chief Financial Officer & Member of Management Board | 1.15M | 1976 |
| Claire Hinshelwood | Chief Financial Officer & Member of Management Board | 1.15M | N/A |
| Sarah Fakih | Executive VP, Head of Global Communications & Investor Relations | 0 | N/A |
| Bernd Mühlenweg | Senior VP & Head of Global Business Development | 0 | N/A |
| Christiane Honisch | SVP Head of Diagnostics | 0 | N/A |
| Uwe Andag | EVP Head of Metabolic Diseases | 0 | N/A |
| Claudia Karnbach | Global Head & Executive VP of Partnering Excellence & Operations | 0 | N/A |
| Christian Dargel | EVice President Global Head of Legal & Compliance | 0 | 1971 |
| David Hallet | Executive Vice President | 0 | N/A |
| Guy Rachmuth | Senior VP of Global Strategic Business Development & Partnerships | 0 | N/A |
| Philip Boehme | Executive Vice President of Partnering & Transformation | 0 | N/A |
Description
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
